Curaleaf International

What Curaleaf International does

Curaleaf International, the wholly-owned international subsidiary of NASDAQ-listed Curaleaf Holdings (CURL), is a vertically integrated medical cannabis company operating across Europe, Canada, and Australasia. Its core operations span EU GMP-certified pharmaceutical-grade cannabis cultivation (25,000 m² in Portugal, 27,000 sq ft in Canada), extraction and API manufacturing (Alicante, Spain), UK MHRA-approved manufacturing (Sunderland), German production and distribution (Four 20 Pharma), and Polish pharmaceutical wholesale (Curaleaf Poland S.A.). The company operates owned clinical channels — Curaleaf Clinic (UK), Sapphire Clinics (Sweden), and Curaleaf Centrum Medyczne (16 Polish cities) — alongside Curaleaf Pharmacy, a GPhC-registered online pharmacy dispensing EU GMP-certified medical cannabis to patients across the UK.

Curaleaf's product portfolio includes dried flowers, oils, capsules, pastilles, and vaporizable extracts, plus the QMID handheld liquid inhalation device — Europe's first CE-certified Class IIa medical device for liquid cannabis formulations, developed with Jupiter Research. The UK Medical Cannabis Registry, covering 55,000+ patients, is the largest real-world evidence database of its kind in Europe and underpins ongoing peer-reviewed research collaborations with Imperial College London and University of Pennsylvania. The Curaleaf Education Platform, launched in June 2026, extends the company's reach into CPD-accredited prescriber training.

Revenue is generated through five streams: pharmaceutical-grade product sales to clinics, pharmacies, and distributors; recurring clinic consultation and treatment revenue; online pharmacy prescription dispensing; wholesale distribution to over 15 countries; and hardware sales of the QMID device. The customer base is fragmented across more than 60,000 UK patients plus clinic networks in Poland and Sweden, with B2B distribution to licensed pharmacies and distributors. International revenue reached $172.5 million in 2025, up 63% year-over-year.

Name

Curaleaf International

Legal name

Curaleaf International Limited

Website

https://curaleafinternational.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

51–100 employees

Short description

Vertically integrated medical cannabis company (subsidiary of NASDAQ-listed Curaleaf Holdings) operating EU GMP-certified cultivation, extraction, and manufacturing across Europe and Canada, serving patients through owned UK, Polish, and Swedish clinics, a GPhC online pharmacy, and wholesale distribution to 15+ countries.

Ownership category

akta.pro rank

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Offices12 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Medical Cannabis Product Sales: Sale of pharmaceutical-grade medical cannabis products including dried flowers, oils, capsules, pastilles, and vaporizable extracts to clinics, pharmacies, and distributors across Europe, Canada, Australia, and New Zealand.
2. Medical Cannabis Clinic Services: Revenue from patient consultations and clinical services through owned clinics including Curaleaf Clinic (UK), Sapphire Clinics (Sweden), and Curaleaf Centrum Medyczne (Poland). Services include expert consultations, personalized treatment plans, and ongoing patient support.
3. Online Pharmacy Dispensing: Dispensing EU GMP-certified medical cannabis products to patients across England, Wales, Scotland, and Northern Ireland through GPhC-registered Curaleaf Pharmacy. Revenue generated from prescription fulfillment.
4. Wholesale and Distribution: Wholesale distribution of medical cannabis products to pharmacies and licensed distributors in over 15 countries. Distribution and export sales operations covering Europe, Australia, and New Zealand.
5. Medical Device Sales: Sales of the CE-certified QMID medical inhalation device for liquid cannabis formulations. Device is distributed through medical cannabis clinics and pharmacies.

Go-to-market motion3 records

Distribution channels6 records

Marketing channels8 records

Core offering

Curaleaf International is a vertically integrated medical cannabis company that cultivates, extracts, manufactures, and distributes EU GMP-certified pharmaceutical-grade cannabis products. The company operates medical cannabis clinics in the UK, Poland, and Sweden; runs a GPhC-registered online pharmacy dispensing prescriptions across the UK; and supplies wholesale and export to pharmacies and distributors in over 15 countries across Europe, Canada, and Australasia. It also markets the QMID CE-certified Class IIa liquid inhalation device and the Curaleaf Education CPD-accredited training platform for healthcare professionals.

Product overview

Curaleaf International operates as a vertically integrated medical cannabis company offering a comprehensive portfolio spanning the entire supply chain from plant to patient. Core offerings include: EU GMP-certified cultivation and manufacturing facilities (Portugal, Spain, Canada); medical cannabis clinics in the UK, Poland, and Sweden; GPhC-registered online pharmacy services; the QMID medical inhalation device (Europe's first CE-certified liquid cannabis device); and the Curaleaf Education Platform for healthcare professional training. The UK Medical Cannabis Registry supports research and evidence-based treatment protocols.

Differentiator

Problem solved

Functional benefit

Brands

• Curaleaf Inhalation Device (QMID): Europe's first handheld liquid inhalation device and the first handheld liquid device ever to earn EU Class IIa medical-device certification, developed in partnership with Jupiter Research.
• Curaleaf Education
• UK Medical Cannabis Registry

Products and services

• Curaleaf Inhalation Device (QMID) Europe's first CE-certified Class IIa handheld liquid inhalation device for medical cannabis formulations, offering precision dosing with 3-second calibrated puff and USB-C rechargeable battery, distributed through medical cannabis clinics and pharmacies across EU member states, UK, Switzerland, Canada, and Australasia.
• Curaleaf Clinic UK's largest, highest-rated, and longest-running CQC-registered medical cannabis clinic providing expert consultations, personalised treatment plans, and ongoing patient support for chronic health conditions, supported by the UK Medical Cannabis Registry.
• Curaleaf Pharmacy GPhC-registered online pharmacy dispensing EU GMP-certified medical cannabis products including oils, dried flowers, capsules, and other formulations directly to patients across England, Wales, Scotland, and Northern Ireland.
• Curaleaf Laboratories UK MHRA-approved manufacturing facility producing EU GMP-certified medical cannabis products, including the first full spectrum medical cannabis manufactured in the UK.
• Curaleaf Centrum Medyczne (formerly Fitokan) Polish medical cannabis clinic operating in 16 cities, offering physician-supervised cannabis-based therapies for chronic pain and neurological disorders.
• Sapphire Clinics Swedish specialist medical cannabis clinic for patients with long-term pain, affiliated with Sweden's first prospective study on prescribed medical cannabis.
• Four 20 Pharma
• Medalchemy
• Northern Green Canada
• Curaleaf Education Platform CPD-accredited online platform providing free medical cannabis education for healthcare professionals across foundational science, core clinical knowledge, and specialist therapeutic areas.
• UK Medical Cannabis Registry

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Jupiter Research LLCcoreStrategic or Co-development Partner · 1 January 2025Partnership with Jupiter Research to develop Europe's first CE-certified medical inhalation device (QMID) for liquid medical cannabis formulations. Joint development of handheld device with precision dosing capabilities.
• Four 20 PharmacoreStrategic or Co-development Partner · 1 January 2022Initial 55% stake acquired in 2022, with remaining 45% completed in April 2026 for full acquisition. EU-GMP & GDP licensed German producer and distributor. Founder Torsten Greif appointed to Curaleaf Board of Directors.
• DalgetyminorStrategic or Co-development Partner · 1 January 2019Cultivation partnership with Dalgety, a Home Office and MHRA-licensed cultivator based in the UK Midlands. Dalgety supplies cannabis as active pharmaceutical ingredient to Curaleaf Laboratories, running 150 varieties at a time with 18-month R&D cycles.
• Imperial College LondoncoreStrategic or Co-development Partner · 1 January 2018Research collaboration with Imperial College London, a leading UK institution, to deepen clinical understanding of cannabis-based medicine. Academic clinician Dr. Mikael Sodergren serves as Chief Medical Officer and is based at Imperial College London.
• University of PennsylvaniacoreStrategic or Co-development Partner · 1 January 2018Clinical research partnership with University of Pennsylvania investigating efficacy of cannabis-based treatments for conditions such as chronic neuropathic pain and cancer-related symptoms.

Scale indicators13 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Tilray Medical: Tilray Medical is a major global medical cannabis cultivator, processor, and distributor with operations in Europe (Germany, Portugal, Italy) and Canada. Directly comparable to Curaleaf International as a vertically integrated competitor supplying EU GMP-certified cannabis to pharmacies and patients across multiple European markets.
• Aurora Cannabis: Aurora Cannabis is a Canadian licensed producer with significant European medical cannabis operations, including EU-GMP cultivation in Canada and distribution across Germany and other EU markets. Competes directly with Curaleaf International in wholesale medical cannabis supply and clinic/pharmacy channels.
• Demecan: Demecan is a German medical cannabis cultivator and distributor with EU GMP certification. Directly competes with Curaleaf's Four 20 Pharma subsidiary in the German market, particularly following Germany's prescription-model transition.
• Bedrocan: Bedrocan is a Dutch medical cannabis producer with EU GMP-certified production supplying European pharmacies and clinical trials. Directly competes with Curaleaf International in the wholesale supply of pharmaceutical-grade cannabis flowers and extracts across European markets.
• Little Green Pharma: Little Green Pharma is an Australian medical cannabis company with EU GMP certification exporting to European markets. Comparable as a smaller vertically integrated medical cannabis producer competing in the same wholesale and pharmacy distribution channels as Curaleaf International.
• OrganiGram Holdings: OrganiGram is a Canadian licensed producer with European medical cannabis ambitions through partnerships. Comparable as a cannabis cultivator pursuing international expansion into European pharmacy and clinic channels similar to Curaleaf International's footprint.
• Sanjevani distributors / Cannamedical (now part of Phytanix): Cannamedical is a German medical cannabis importer and distributor supplying pharmacies across Europe. Directly competes with Curaleaf's wholesale distribution arm in Germany and other European markets.

Broad incumbents

• Canopy Growth Corporation: Canopy Growth is a large publicly-traded cannabis company with European medical cannabis operations through its Spectrum Therapeutics brand. Overlaps with Curaleaf International on EU GMP-certified medical cannabis distribution but operates a broader portfolio across recreational and consumer products.
• Stada Arzneimittel AG: Stada is a major European generics and consumer health pharmaceutical company that has partnered with producers (e.g., THC Pharm) to distribute medical cannabis in Germany. Broadly comparable as an established European pharmaceutical distribution partner that intersects with Curaleaf's Four 20 Pharma German operations.

Emerging players

• Khiron Life Sciences: Khiron is a medical cannabis company with European operations through Khiron Europe, focused on clinic networks and patient access in Germany, UK, and Spain. Comparable as a clinic-led medical cannabis player targeting similar patient populations and prescriber channels as Curaleaf International.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights7 records

Customer concentration

• Xx.com/curaleafint
• LinkedInlinkedin.com/company/curaleafint

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Curaleaf International